Stay informed with announcements, scientific insights, press releases, and selected publications. Discover how our multidisciplinary approach—spanning immunology, genomics, protein engineering, and computational biology—is advancing transformative treatments for patients.
Unleashing NK cells by removing molecular brakes
New Cancer Cell paper: We discovered molecular brakes (UBE2F, ARIH2) that limit NK cell cancer-fighting ability. Targeting these proteins could enhance immunotherapy effectiveness while avoiding toxicity—opening doors to safer, more powerful treatments.
Sticking Immune Biology together with Molecular Glue
Molecular glues are revolutionising drug discovery. We explore their role in targeted protein degradation and how our novel Immunoglue™ platform advances these compounds toward treating cancer and immune disorders.
A Powerhouse Cytokine for Cancer Immunotherapy
There are many different types of cytokines with different effects on the immune system, but IL-12 really stands out in the context of cancer. We investigate what this cytokine is and how it functions in cell-mediated immunity.
A Major Obstacle in Cancer Therapy
Explores the concept of the cold tumor microenvironment, the difference between a cold tumors and hot tumors, and how immunotherapy can heat up cold tumors.
